B
Biocon
India - Bangalore
BiotechnologyFocus: Fully Integrated Drug Company
Error: Unreachable/Blocked
OncologyNeurologyCardiovascularNephrologyInfectious Diseases
Open Jobs
0
Products & Portfolio (36)
1 discontinued product not shown
ATORVASTATIN CALCIUM
atorvastatin calcium
Post-LOE
ORAL · TABLET
selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin also reduces LDL production and the number of LDL particles.
type 2 diabetes mellitusheart failure
2022
30
AUKELSO
denosumab-kyqq
Launch
mAbINJECTION · INJECTABLE
RANK Ligand Blocking Activity
postmenopausal women with osteoporosis at high risk for fracturedefinedmultiple risk factors for fracture+6 more
2025
30
BOSAYA
denosumab-kyqq
Launch
mAbINJECTION · INJECTABLE
RANK Ligand Blocking Activity
postmenopausal women with osteoporosis at high risk for fracturedefinedmultiple risk factors for fracture+6 more
2025
30
CARBIDOPA AND LEVODOPA
carbidopa,levodopa
Pre-Launch
CAPSULE, EXTENDED RELEASE
Mechanism of Action Parkinson's disease is a progressive, neurodegenerative disorder of the extrapyramidal nervous system affecting the mobility and control of the skeletal muscular system. Its characteristic features include resting tremor, rigidity, and bradykinetic movements. Symptomatic treatments, such as levodopa therapies, may permit the patient better mobility. Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because it does not cross the blood-brain barrier. However, levodopa, the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.
the treatment of Parkinson's diseasepost-encephalitic parkinsonismsymptomatic parkinsonism+5 more
DAPTOMYCIN
daptomycin
Post-LOE
INTRAVENOUS · POWDER
12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ]. 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for certain pathogens, including S. aureus . The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with daptomycin for injection. 12.3 Pharmacokinetics Daptomycin for injection Administered over a 30-Minute Period in Adults The mean and standard deviation (SD) pharmacokinetic parameters of daptomycin at steady-state following intravenous (IV) administration of daptomycin for injection over a 30-minute period at 4 to 12 mg/kg every 24h to healthy young adults are summarized in Table 11. Table 11: Mean (SD) Daptomycin Pharmacokinetic Parameters in Healthy Adult Volunteers at Steady-State Dose Daptomycin for injection was administered by IV infusion over a 30-minute period. Doses of daptomycin for injection in excess of 6 mg/kg have not been approved. (mg/kg) Pharmacokinetic Parameters AUC 0-24 , area under the concentration-time curve from 0 to 24 hours; t 1/2 , elimination half-life; V ss , volume of distribution at steady-state; CL T , total plasma clearance; C max , maximum plasma concentration. AUC 0-24 (mcg∙h/mL) t 1/2 (h) V ss (L/kg) CL T (mL/h/kg) C max (mcg/mL) 4 (N=6) 494 (75) 8.1 (1.0) 0.096 (0.009) 8.3 (1.3) 57.8 (3.0) 6 (N=6) 632 (78) 7.9 (1.0) 0.101 (0.007) 9.1 (1.5) 93.9 (6.0) 8 (N=6) 858 (213) 8.3 (2.2) 0.101 (0.013) 9.0 (3.0) 123.3 (16.0) 10 (N=9) 1039 (178) 7.9 (0.6) 0.098 (0.017) 8.8 (2.2) 141.1 (24.0) 12 (N=9) 1277 (253) 7.7 (1.1) 0.097 (0.018) 9.0 (2.8) 183.7 (25.0) Daptomycin pharmacokinetics were generally linear and time-independent at daptomycin for injection doses of 4 to 12 mg/kg every 24h administered by IV infusion over a 30-minute period for up to 14 days. Steady-state trough concentrations were achieved by the third daily dose. The mean (SD) steady-state trough concentrations attained following the administration of 4, 6, 8, 10, and 12 mg/kg every 24h were 5.9 (1.6), 6.7 (1.6), 10.3 (5.5), 12.9 (2.9), and 13.7 (5.2) mcg/mL, respectively. Daptomycin for injection Administered over a 2-Minute Period in Adults Following IV administration of daptomycin for injection over a 2-minute period to healthy adult volunteers at doses of 4 mg/kg (N=8) and 6 mg/kg (N=12), the mean (SD) steady-state systemic exposure (AUC) values were 475 (71) and 701 (82) mcg∙h/mL, respectively. Values for maximum plasma concentration (C max ) at the end of the 2-minute period could not be determined adequately in this study. However, using pharmacokinetic parameters from 14 healthy adult volunteers who received a single dose of daptomycin for injection 6 mg/kg IV administered over a 30-minute period in a separate study, steady-state C max values were simulated for dapt
pneumonialeft-sided infective endocarditis due to Sskin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates)+12 more
2024
30
DASATINIB
dasatinib
Post-LOE
SMORAL · TABLET
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro , dasatinib was active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib could overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
older with Ph+ CML in chronic phasenewly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phaseleukemia
2025
30
EVEROLIMUS
everolimus
Post-LOE
ORAL · TABLET
Protein Kinase Inhibitors
organ rejection in adult patients at low to moderate immunologic risk receiving a kidney transplant [ see Clinical Studies (14allograft rejection in adult patients receiving a liver transplant
2025
30
EVEROLIMUS
everolimus
Post-LOE
ORAL · TABLET, FOR SUSPENSION
Protein Kinase Inhibitors
older with TSC for the treatment of SEGA
2026
30
EVEROLIMUS
everolimus
Post-LOE
ORAL · TABLET
Protein Kinase Inhibitors
older with TSCpostmenopausal women with advanced hormone receptor-positiveHER2-negative breast cancer in combination with exemestane+5 more
2021
30
FINGOLIMOD HYDROCHLORIDE
fingolimod
Post-LOE
ORAL · CAPSULE
metabolite, fingolimod-phosphate. Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.
relapsing forms of multiple sclerosis (MS)to include clinically isolated syndromerelapsing-remitting disease+3 more
2019
30
JOBEVNE
bevacizumab-nwgd
Launch
mAbINJECTION · INJECTABLE
Vascular Endothelial Growth Factor-directed Antibody Interactions
2025
30
KIRSTY
water
Launch
SOLUTION · INJECTION
insulin, including insulin aspart products, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
glycemic control in adults
2025
30
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 37 approved products
Top TAs: Oncology, Cardiovascular, Infectious Diseases
Portfolio Health
Pre-Launch4 (11%)
Launch4 (11%)
Growth2 (5%)
Post-LOE27 (73%)
37 total products
Therapeutic Area Focus
Oncology
7 marketed
Cardiovascular
4 marketed
Infectious Diseases
3 marketed
Neurology
3 marketed
Musculoskeletal
2 marketed
Immunology
2 marketed
Metabolic Diseases
2 marketed
Nephrology
2 marketed
Marketed
Pipeline